Navigation Links
Verenium Corporation To Announce Fourth Quarter And Year End 2012 Financial Results
Date:3/18/2013

nce as of December 31, 2012, near-term opportunities and long-term growth prospects, the impact of Verenium's restatement of certain of its historical financial statements on its consolidated balance sheets and consolidated statement of operations for the relevant periods and its cash position, and Verenium's San Diego facility and the related lease.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's audited financial results, capital expenditures and cash position for the year ended and as of December 31, 2012 being different from Verenium's estimated financial results, capital expenditures and cash position, the actual impact of Verenium's restatement of certain of its historical financial statements on its consolidated balance sheets and consolidated statement of operations for the relevant periods and its cash position being different from the estimated impact, Verenium's strategic focus, technologies, products and product candidates and product pipeline (including Verenium's ability to identify, develop and commercialize new products and product candidates, either independently or with collaborators or partners, and market demand for those products and product candidates), dependence on patents and proprietary rights,  protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements,  its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies, th
'/>"/>
SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology news :

1. Celladon Corporation Receives Notice of Allowance from United States Patent and Trademark Office
2. Sanford-Burnham and Intrexon Corporation establish collaboration to accelerate stem cell research
3. Statistics & Data Corporation Selects MedNet Solutions As Strategic Technology Partner
4. Eliza Corporation and BlueCross BlueShield of South Carolina Drive Awareness and Healthier Behavior to Increase Colorectal Cancer Screenings by 45 Percent
5. ShanghaiBio Corporation Partners with Ingenuity Systems to Address Challenges in Analysis and Interpretation of Genomics Data
6. Medbox, Inc. Announces Top-Tier Rating by Dun & Bradstreet Credibility Corporation
7. Scripps Research and Takeda Pharmaceuticals announce expanded research collaboration
8. Spiral Genetics Closes $3 Million in Funding Led by DFJ and Announces Partnership with Omicia
9. Wake Forest Innovations Announces New Commercialization Developments
10. MARC Travel Awards announced for Immunohistochemistry and Microscopy (IHCM) Short Course 2013
11. FASEB MARC Travel Awards announced for the 2013 American College of Sports Medicine Northwest Chapter Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... most ideal source of nutrition for infants and ... the evolution and civilizations of human beings. Unlike ... number of bacterial species, including some opportunistic pathogens ... to scientists and physicians. , Indeed, the existence ... result of co-evolutionary and co-adaptive interactions between the ...
(Date:9/2/2014)... integrity? Tell the truth; everyone has a tipping point. We ... lie if the benefit is great enough. Now, scientists have ... that decision. , The result was published online this ... prefer to be honest, even if lying is beneficial," said ... at the Virginia Tech Carilion Research Institute , where ...
(Date:9/2/2014)... propensity for eating anything, including each other, camel crickets ... North Carolina State University finds that non-native camel cricket ... States. , "The good news is that camel crickets ... humans," says Dr. Mary Jane Epps, a postdoctoral researcher ... about the research. , The research stems from a ...
Breaking Biology News(10 mins):Are human breast milk microbiome 'neutral'? 2Are human breast milk microbiome 'neutral'? 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4Researchers find Asian camel crickets now common in US homes 2
... the triangle depicting how many servings of each food ... knows about MyPlate - the circle showing what a healthy ... United States Department of Agriculture (USDA) to help American consumers ... icon that prompts us to think about what,s on our ...
... gene therapy holds promise for the treatment of devastating genetic ... have been unclear. In a study online December 26th ... by Cell Press, researchers evaluated a patient with a genetic ... after he had undergone a gene therapy procedure as part ...
... neurodegenerative disorders, and drugs without significant side effects ... Institute of Synergon Consulting in Romania, led by ... is a transcription co-activator required for consolidation of ... same time involved in DNA replication and repair, ...
Cached Biology News:Who is using MyPlate? 2Gene therapy for human skin disease produces long-term benefits 2
(Date:9/2/2014)... , September 2, 2014 Persistence ... Membrane Technology in Pharmaceutical, Biopharma and Life Sciences: ... by 2019" the global membrane technology market for pharmaceutical, biopharma and ... 2014 and is expected to grow at a CAGR ... estimated value of USD 10,886.0 million in 2019. ...
(Date:9/2/2014)... Myriant Corporation, a global renewable chemicals ... agreement with Azelis Group, a specialty chemicals distribution ... in the Nordics, Benelux, France, Iberia, Italy, the ... industrial and base chemicals markets. , “As a ... chemical portfolio with extensive distribution networks providing Myriant ...
(Date:9/2/2014)... , Sept. 2, 2014  Xencor, Inc. (NASDAQ: ... developing engineered monoclonal antibodies for the treatment of ... today announced the appointment of Debra Zack ... the appointment of Lloyd Rowland , senior ... "Debra,s expertise in biologics clinical ...
(Date:9/2/2014)... 2, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... orders consist of three large odour control systems for waste ... "These orders are consistent with the market resurgence in ... , President and CEO. "After a difficult period of restraint ... beginning to see sales growth. Our lower cost structure, technology ...
Breaking Biology Technology:Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3
... that it,has received the European CE Mark (Conformite Europeene) ... CE Mark certifies,that the product has met EU health, ... Granted in the Netherlands, the,registration will allow the system ... countries around the world that recognize the CE Mark. ...
... Calif., Oct. 29 Cliniqa Corporation (San,Marcos, ... is pleased to,announce the acquisition of the ... Diego, CA), a wholly owned subsidiary of ... manufacturer of clinical,diagnostic products focusing on clinical ...
... to Focus on Sales Growth and Product ... BioLife Solutions,Inc. (OTC Bulletin Board: BLFS), a ... and cryopreservation media products for,cells, tissues, and ... product,manufacturing, warehousing, and customer order fulfillment to ...
Cached Biology Technology:Diamics Receives European CE Mark Approval for Its Pap-Map(TM) System for Cervical Cancer Screening 2Cliniqa Corporation Completes Asset Acquisition of Reagents Applications, Inc. 2BioLife Solutions Outsourcing Manufacturing, Warehousing, and Order Fulfillment to Bioserv Corporation 2BioLife Solutions Outsourcing Manufacturing, Warehousing, and Order Fulfillment to Bioserv Corporation 3